Allergy Clinical Trial
Official title:
An Investigation of the Effectiveness of the Mediterranean Diet in Pregnant Women at Risk of Developing Allergy in Their Infants: Pilot Randomised Controlled Trial
There has been an increase in asthma and allergic disease prevalence, especially in children.
Given the high prevalence, and the associated high disease burden and costs, there is an
urgent need to identify effective strategies for the primary prevention of asthma and
allergy. A systematic review of the literature has found strong supportive epidemiological
evidence of a protective role for the Mediterranean Diet (MD).
The investigators aim is to undertake a pilot trial in a sample of pregnant women to
establish recruitment, retention, a measurable change to a dietary intervention encouraging
greater adherence to a MD during pregnancy, and acceptability of the dietary advice and diet
modifications.
This pilot study will be a 2-arm randomised controlled trial (RCT) in a sample population of
around 50 Scottish pregnant women.
This work ultimately aims to contribute to improving health outcomes through seeking to
reduce the incidence of asthma and allergic problems. This pilot trial will prove invaluable
in informing the subsequent planned definitive parallel group RCT.
Aims
The primary aims of this pilot trial are to investigate rates of maternal recruitment and
retention, and adherence with a MD during the latter two trimesters of pregnancy (i.e. weeks
12 to 36). The secondary aims are to determine whether there is any subsequent measurable
change in the Mediterranean Diet score and whether the dietary advice and diet modifications
are acceptable.
Research questions
1. What are the recruitment and retention rates of pregnant mothers whose infants are at
high risk of atopic disease?
2. Is the advice and dietary modification acceptable to participants?
3. To what extent are mothers able to adhere to a MD?
4. Can a MD score be increased in pregnancy?
5. Can a measurable change in a biomarker of oxidative stress be detected as a result of
adherence to a MD?
6. Can any increases in MD be sustained during pregnancy?
Design
1. Trial design This is a two-arm pilot RCT. Trial participants will be recruited from 2-3
hospitals/community treatment centres in Scotland.
2. Participant recruitment
Pregnant women aged 16 years and above will be sent a letter of invitation, information
for participants, and a consent form for the trial with their dating scan appointment by
the hospital. Interested participants will be invited to contact the researcher by text,
phone or email to discuss the project and answer any questions they may have; they will
then be screened for eligibility to take part in the trial.
Eligibility of high risk women is defined as: those with one or more first degree blood
relatives with atopic dermatitis (eczema), a food allergy, allergic rhinitis (hay fever)
or asthma, using the question 'Do you, the mother, or the father or sibling of the baby
have an allergic disease: eczema, a food allergy, hay fever or asthma?' Responses will
be recorded on the screening questionnaire.
The researcher will send to the participant a food frequency questionnaire for
completion at home and a urine container with instructions to fill the container on the
day of the scan and bring it, with the Consent form and the completed FFQ along with
them to hand over to the researcher. The urine specimen will be used for the analysis of
markers of oxidative stress, antioxidant activity and nitric oxide (NO) synthesis. The
researcher will greet the participant in the waiting area of the clinic prior to their
dating scan where their consent form, urine sample and FFQ will be collected. After
their scan, consenting eligible participants will complete a baseline MD questionnaire.
3. Intervention
The intervention is a 15 minute dietary advice session directed at increasing the MD
score, with subsequent telephone support sessions throughout the pregnancy.
Intervention arm
Mothers randomised to the intervention arm will meet with the project researcher when
visiting the hospital for their first dating scan. After the scan, participants will
receive a 15 minute dietary advice session, encouraging the consumption of particular
foods that are consistent with the MD, and the key messages will be supplemented through
written/visual materials, and through regular supportive telephone calls. No energy
restrictions will be suggested. A £10 supermarket voucher will be given to the
participants.
The first follow-up by the researcher will be by telephone 12 weeks post-baseline MD
questionnaire to inform them they will receive the second MD questionnaire and reply
envelope for completion and return. A further supermarket voucher to the value of £10
will be sent to the participant on receipt of the completed form.
Two weeks prior to the 24 weeks post-baseline MD questionnaire the project researcher
will contact participants by phone and arrange a home visit. When visited at home by the
researcher, a third MD questionnaire and second FFQ will be completed and handed to the
researcher and a urine sample will be obtained.
Free and continuous telephone access to the researcher will be available throughout the
study.
Control arm
Mothers randomised to the control arm will meet with the project researcher when
visiting the hospital for their first dating scan. The participant will not receive the
15 minute dietary advice session. A £10 supermarket voucher will be given to the
participants. The first follow-up by the researcher will be by telephone 12 weeks
post-baseline MD questionnaire to inform them they will receive the second MD
questionnaire and reply envelope for completion and return. A further supermarket
voucher to the value of £10 will be sent to the participant on receipt of the completed
form.
Two weeks prior to the 24 weeks post-baseline MD questionnaire the project researcher
will contact participants by phone and arrange a home visit. When visited at home by the
researcher, a third MD questionnaire and second FFQ will be completed and handed to the
researcher and a urine sample will be obtained.
4. Randomisation
Allocation to the intervention or control arm will be via pre-randomised sealed
envelopes, based on a predetermined random number allocation, restricted by recruitment
site. This restricted randomisation will be carried out by an independent statistician.
5. Follow-up Participants will be enrolled for a total of ~7 months (i.e. from 12-36 weeks
of pregnancy).
Outcome measures
- Recruitment rate (i.e. the proportion of those invited to take part compared with the
number of consenting women)
- Retention rate (i.e. the proportion of those starting the study to those finishing)
- Change in MD score from baseline to 24 and 36 weeks of pregnancy
- Change in oxidative stress and whole-body NO production
- Acceptability of dietary advice and diet modifications
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02032056 -
Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period
|
N/A | |
Completed |
NCT01842711 -
Cumulative Irritation Patch Test
|
N/A | |
Completed |
NCT01633840 -
New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges
|
N/A | |
Completed |
NCT00554983 -
Efficacy and Safety From a Recombinant Folding Variant of Bet v 1
|
Phase 3 | |
Completed |
NCT00997971 -
Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein
|
Phase 3 | |
Completed |
NCT00331929 -
Respiratory Health Study of Children in Kiryat Tivon
|
N/A | |
Completed |
NCT00220753 -
Air Cleaners for Children and Adolescents With Asthma and Dog Allergy
|
N/A | |
Completed |
NCT00232518 -
Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis
|
N/A | |
Completed |
NCT04126096 -
Negative Predictive Value and NIC of Beta-Lactam Antibiotics.
|
N/A | |
Completed |
NCT04046731 -
Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation
|
N/A | |
Completed |
NCT04004351 -
Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
|
||
Not yet recruiting |
NCT05997784 -
Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
|
||
Completed |
NCT04418999 -
Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
|
Early Phase 1 | |
Completed |
NCT04186949 -
Early Origins of Allergy and Asthma
|
||
Completed |
NCT02127801 -
Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants
|
Phase 1 | |
Enrolling by invitation |
NCT05011071 -
The Alberta BLOOM Premature Child Study
|
||
Not yet recruiting |
NCT06330974 -
Allergy, Asthma, and Atopic Eczema in Finland
|
||
Completed |
NCT02596321 -
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
|
Phase 3 | |
Terminated |
NCT02601690 -
Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
|
||
Completed |
NCT02306473 -
The Leaky Lung Test
|
Early Phase 1 |